Lucid Diagnostics closes $28.75M public offering of 28.75M shares at $1.00/share

Lucid Diagnostics Inc.

Closed underwritten public offering of 28,750,000 shares at $1.00 per share, including full exercise of underwriters' option for 3,750,000 additional shares.
Net proceeds expected to be approximately $26.9 million after deducting underwriting discounts and offering expenses.
Proceeds will be used for working capital and general corporate purposes.
Canaccord Genuity and BTIG acted as joint bookrunners; Maxim Group LLC served as co-manager.
Offering made under existing effective shelf registration statement (Form S-3, File No. 333-268560).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.